相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Clinical efficacy of WT1 peptide vaccination in patients with acute myelogenous leukemia and myelodysplastic syndrome
Masaki Yasukawa et al.
AMERICAN JOURNAL OF HEMATOLOGY (2009)
A clinical and immunologic phase 2 trial of Wilms tumor gene product 1 (WT1) peptide vaccination in patients with AML and MDS
Ulrich Keilholz et al.
BLOOD (2009)
CD8+ T-cell responses to tumor-associated antigens correlate with superior relapse-free survival after allo-SCT
M. Kapp et al.
BONE MARROW TRANSPLANTATION (2009)
The Prioritization of Cancer Antigens: A National Cancer Institute Pilot Project for the Acceleration of Translational Research
Martin A. Cheever et al.
CLINICAL CANCER RESEARCH (2009)
WT1 IgG antibody for early detection of nonsmall cell lung cancer and as its prognostic factor
Yusuke Oji et al.
INTERNATIONAL JOURNAL OF CANCER (2009)
WT1 (WILMS TUMOR 1) PEPTIDE IMMUNOTHERAPY FOR CHILDHOOD RHABDOMYOSARCOMA: A Case Report
Hideaki Ohta et al.
PEDIATRIC HEMATOLOGY AND ONCOLOGY (2009)
Phase II clinical trial of Wilms tumor 1 peptide vaccination for patients with recurrent glioblastoma multiforme
Shuichi Izumoto et al.
JOURNAL OF NEUROSURGERY (2008)
A WT1 protein-derived, naturally processed 16-mer peptide, WT1332, is a promiscuous helper peptide for induction of WT1-specific Th1-type CD4+ T cells
Fumihiro Fujiki et al.
MICROBIOLOGY AND IMMUNOLOGY (2008)
Identification of a WT1 protein-derived peptide, WT1187, as a HLA-A*0206-restricted, WT1-specific CTL epitope
Zheyu Li et al.
MICROBIOLOGY AND IMMUNOLOGY (2008)
Leukemia-associated antigen-specific T-cell responses following combined PR1 and WT1 peptide vaccination in patients with myeloid malignancies
Katayoun Rezvani et al.
BLOOD (2008)
Wilms tumor gene WT1 peptide-based immunotherapy induced a minimal response in a patient with advanced therapy-resistant multiple myeloma
Akihiro Tsuboi et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2007)
Graft-versus-leukemia effects associated with detectable Wilms tumor-1-specific T lymphocytes after allogeneic stem-cell transplantation for acute lymphoblastic leukemia
Katayoun Rezvani et al.
BLOOD (2007)
Peptide epitopes from the Wilms' tumor 1 oncoprotein stimulate CD4+ and CD8+ T cells that recognize and kill human malignant mesothelioma tumor cells
Rena J. May et al.
CLINICAL CANCER RESEARCH (2007)
Clinical and immunologic responses to very low-dose vaccination with WT1 peptide (5 μg/body) in a patient with chronic myelomonocytic leukemia
Manabu Kawakami et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2007)
WT1 (Wilms' tumor 1) peptide immunotherapy for renal cell carcinoma
Tatsuo Iiyama et al.
MICROBIOLOGY AND IMMUNOLOGY (2007)
Identification of a highly immunogenic HLA-A*01-binding T cell epitope of WT1
Anne Marie Asemissen et al.
CLINICAL CANCER RESEARCH (2006)
Improved human T-cell responses against synthetic HLA-0201 analog peptides derived from the WT1 oncoprotein
J. Pinilla-Ibarz et al.
LEUKEMIA (2006)
Monitoring of WT1-specific cytotoxic T lymphocytes after allogeneic hematopoietic stem cell transplantation
Yuriko Morita et al.
INTERNATIONAL JOURNAL OF CANCER (2006)
Defining MHC class II T helper epitopes for WT1 tumor antigen
H Kobayashi et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2006)
Antiapoptotic function of 17AA(+) WT1 (Wilms' tumor gene) isoforms on the intrinsic apoptosis pathway
K. Ito et al.
ONCOGENE (2006)
AML1-ETO rapidly induces acute myeloblastic leukemia in cooperation with the Wilms tumor gene, WT1.
S Nishida et al.
BLOOD (2006)
A phase I/II trial of a WT1 (Wilms' tumor gene) peptide vaccine in patients with solid malignancy: Safety assessment based on the phase I data
Satoshi Morita et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2006)
Wilms' tumor gene WT1 17AA(-)/KTS(-) isoform induces morphological changes and promotes cell migration and invasion in vitro
T Jomgeow et al.
CANCER SCIENCE (2006)
Detection of Wilms' tumor antigen-specific CTL in tumor-draining lymph nodes of patients with early breast cancer
R Gillmore et al.
CLINICAL CANCER RESEARCH (2006)
T-cell responses directed against multiple HLA-A*0201-restricted epitopes derived from Wilms' tumor 1 protein in patients with leukemia and healthy donors: Identification, quantification, and characterization
K Rezvani et al.
CLINICAL CANCER RESEARCH (2005)
WT1235, a ninemer peptide derived from Wilms' tumor gene product, is a candidate peptide for the vaccination of HLA-A*0201-positive patients with hematopoietic malignancies
ZY Li et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2005)
Direct recognition and lysis of leukemia cells by WT1-specific CD4+ T lymphocytes in an HLA class II-restricted manner
Y Guo et al.
BLOOD (2005)
Cancer immunotherapy targeting Wilms' tumor gene WT1 product
H Sugiyama
EXPERT REVIEW OF VACCINES (2005)
Ex vivo characterization of multiepitopic tumor-specific CD8 T cells in patients with chronic myeloid leukemia:: Implications for vaccine development and adoptive cellular immunotherapy
M Gannagé et al.
JOURNAL OF IMMUNOLOGY (2005)
Th1-biased humoral immune responses against Wilms tumor gene WT1 product in the patients with hematopoietic malignancies
F Wu et al.
LEUKEMIA (2005)
The Wilms' tumor gene WT1 is a common marker of progenitor cells in fetal liver
K Kanato et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2005)
mRNA expression of leukemia-associated antigens in patients with acute myeloid leukemia for the development of specific immunotherapies
J Greiner et al.
INTERNATIONAL JOURNAL OF CANCER (2004)
Absence of mutations in the Wilms' tumor gene WT1 in primary breast cancer
Y Oji et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2004)
Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression
Y Oka et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
Overexpression of the Wilms' tumor gene WT1 in pancreatic ductal adenocarcinoma
Y Oji et al.
CANCER SCIENCE (2004)
Complete remission in a patient with recurrent acute myeloid leukemia induced by vaccination with WT1 peptide in the absence of hematological or renal toxicity
V Mailander et al.
LEUKEMIA (2004)
Myeloma cells are highly sensitive to the granule exocytosis pathway mediated by WT1-specific cytotoxic T lymphocytes
T Azuma et al.
CLINICAL CANCER RESEARCH (2004)
Overexpression of the Wilms' tumor gene WT1 in primary astrocytic tumors
Y Oji et al.
CANCER SCIENCE (2004)
WT1 peptide-based immunotherapy for patients with lung cancer: Report of two cases
A Tsuboi et al.
MICROBIOLOGY AND IMMUNOLOGY (2004)
Functional leukemia-associated antigen-specific memory CD8+ T cells exist in healthy individuals and in patients with chronic myelogenous leukemia before and after stem cell transplantation
K Rezvani et al.
BLOOD (2003)
Overexpression of the Wilms' tumor gene WT1 in colorectal adenocarcinoma
Y Oji et al.
CANCER SCIENCE (2003)
Overexpression of the Wilms' tumor gene WT1 in primary thyroid cancer
Y Oji et al.
CANCER SCIENCE (2003)
Overexpression of the Wilms tumor gene WT1 in head and neck squamous cell carcinoma
Y Oji et al.
CANCER SCIENCE (2003)
The lck promoter-driven expression of the Wilms tumor gene WT1 blocks intrathymic differentiation of T-lineage cells
H Li et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2003)
Overexpression of the Wilms' tumor gene WT1 in human bone and soft-tissue sarcomas
T Ueda et al.
CANCER SCIENCE (2003)
The usefulness of monitoring WT1 gene transcripts for the prediction and management of relapse following allogeneic stem cell transplantation in acute type leukemia
H Ogawa et al.
BLOOD (2003)
Monitoring minimal residual disease in leukemia using real-time quantitative polymerase chain reaction for Wilms tumor gene (WT1)
H Tamaki et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2003)
Enhanced induction of human WT1-specific cytotoxic T lymphocytes with a 9-mer WT1 peptide modified at HLA-A*2402-binding residues
A Tsuboi et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2002)
Two distinct HLA-A0201-presented epitopes of the Wilms tumor antigen can function as targets for leukemia-reactive CTL
I Bellantuono et al.
BLOOD (2002)
Quantitative assessment of WT1 expression by real time quantitative PCR may be a useful tool for monitoring minimal residual disease in acute leukemia patients
D Cilloni et al.
LEUKEMIA (2002)
CD8 T-cell responses to Wilms tumor gene product WT1 and proteinase 3 in patients with acute myeloid leukemia
C Scheibenbogen et al.
BLOOD (2002)
Overexpression of the Wilms' tumor gene WT1 in de novo lung cancers
Y Oji et al.
INTERNATIONAL JOURNAL OF CANCER (2002)
Prediction of an HLA-DR-binding peptide derived from Wilms' tumour 1 protein and demonstration of in vitro immunogenicity of WT1(124-138)-pulsed dendritic cells generated according to an optimised protocol
AJ Knights et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2002)
Humoral immune responses against Wilms tumor gene WT1 product in patients with hematopoietic malignancies
OA Elisseeva et al.
BLOOD (2002)
Very low frequencies of human normal CD34+ haematopoietic progenitor cells express the Wilms' tumour gene WT1 at levels similar to those in leukaemia cells
N Hosen et al.
BRITISH JOURNAL OF HAEMATOLOGY (2002)
Identification of a novel WT1-derived peptide which induces human leucocyte antigen-A24-restricted anti-leukaemia cytotoxic T lymphocytes
T Azuma et al.
BRITISH JOURNAL OF HAEMATOLOGY (2002)
Cytotoxic T-lymphocyte responses elicited to Wilms' tumor gene WT1 product by DNA vaccination
A Tsuboi et al.
JOURNAL OF CLINICAL IMMUNOLOGY (2000)
Cancer immunotherapy targeting Wilms' tumor gene WT1 product
Y Oka et al.
JOURNAL OF IMMUNOLOGY (2000)
分享论文
